Featured Research

from universities, journals, and other organizations

University of Kentucky Researcher Discovers Drug That Shows Promise In Treating Rare Cancer

Date:
October 4, 2000
Source:
University Of Kentucky Medical Center
Summary:
New research published recently in the journal Thyroid shows that paclitaxel (Taxol®) has significant clinical activity against anaplastic thyroid carcinoma (ATC).

New research published recently in the journal Thyroid shows that paclitaxel (Taxol®) has significant clinical activity against anaplastic thyroid carcinoma (ATC). The research study was led by Kenneth B. Ain, M.D., associate professor, Division of Endocrinology, Department of Internal Medicine, University of Kentucky College of Medicine, and Medical Service at the Veterans Affairs Medical Center in Lexington.

This study is an example of how treatments can be developed from basic research through clinical trials in patients entirely by faculty at the UK Chandler Medical Center and the VAMC in Lexington.

Paclitaxel is a compound that was isolated from the bark of the Pacific yew tree. The U.S. Food and Drug Administration has approved paclitaxel to treat breast and ovarian cancer, non-small-cell lung cancer, and AIDS-related Kaposi's sarcoma.

ATC is a rare disease with no effective therapies. It is the most aggressive solid cancer and is always fatal, with a mean survival time after diagnosis of two to five months with treatment. ATC accounts for 1.6 percent of all thyroid cancers, and there are about 300 cases in the United States each year.

Ain created the thyroid cancer program at the UK Chandler Medical Center. Patients from around the world receive clinical care through the program.

The recently published study was a Phase II trial, or a clinical trial required for approval of a drug indication by the Food and Drug Administration that focuses on the effectiveness of a single drug. In the study, paclitaxel was infused continuously over 96 hours every three weeks for one to six treatments. Of the 19 evaluable patients, 53 percent showed a response to the drug, meaning their survival time increased. However, treatment with paclitaxel did not alter the mortality rate.

Ain's team currently is researching adding other drugs to paclitaxel in an effort to find more effective treatments for ATC.


Story Source:

The above story is based on materials provided by University Of Kentucky Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Kentucky Medical Center. "University of Kentucky Researcher Discovers Drug That Shows Promise In Treating Rare Cancer." ScienceDaily. ScienceDaily, 4 October 2000. <www.sciencedaily.com/releases/2000/09/000913205318.htm>.
University Of Kentucky Medical Center. (2000, October 4). University of Kentucky Researcher Discovers Drug That Shows Promise In Treating Rare Cancer. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2000/09/000913205318.htm
University Of Kentucky Medical Center. "University of Kentucky Researcher Discovers Drug That Shows Promise In Treating Rare Cancer." ScienceDaily. www.sciencedaily.com/releases/2000/09/000913205318.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins